Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors
Guntle, Gerald P.
Mash, Eugene A.
Korn, Ronald L.
AffiliationUniv Arizona, Arizona Canc Ctr
Univ Arizona, Dept Chem & Biochem
MetadataShow full item record
PublisherIMPACT JOURNALS LLC
CitationMagnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors 2017, 8 (60) Oncotarget
Rights© Raghunand et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0).
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at firstname.lastname@example.org.
AbstractRRx-001 is an anticancer agent that subjects cancer cells to reactive oxygen/nitrogen species (ROS/RNS) and acts as an epigenetic modifier. We have used a thiol-bearing MRI contrast agent, Gd-LC7-SH, to investigate the pharmacodynamics of RRx-001 in CHP-100 Ewing's Sarcoma, HT-29 colorectal carcinoma, and PANC-1 pancreatic carcinoma xenografts in SCID mice. Binding of Gd-LC7-SH to the Cys34 residue on plasma albumin prolongs retention in the tumor microenvironment and increases tumor enhancement on MRI. Mice were imaged by MRI and in vivo T1 maps acquired 50 min (T1(50 min)) after injection of 0.05 mmol/kg Gd-LC7-SH (i.v.) at baseline and 1, 24, and 72 h post-treatment with 10 mg/kg RRx-001 (i.v.). Consistent with an indirect thiol-modifying activity of RRx-001, tumor T150 min at 1 h post-drug was significantly longer than pre-drug tumor T150 min in all three tumor models, with the T150 min remaining significantly longer than baseline through 72 h post-drug in the HT-29 and PANC-1 tumors. The T150 min of CHP-100 tumors recovered to baseline by 24 h post-drug, suggesting a robust anti-oxidant response to the RRx-001 challenge that was presaged by a marked increase in perfusion at 1 h post-drug measured by DCE-MRI. MRI enhanced with Gd-LC7-SH provides a mechanistically rational biomarker of RRx-001 pharmacodynamics.
VersionFinal published version
SponsorsEpicentRx; National Institutes of Health [R01-CA118359, P30-CA023074]
Except where otherwise noted, this item's license is described as © Raghunand et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0).
- Tumor Xenograft Response to Redox-Active Therapies Assessed by Magnetic Resonance Imaging Using a Thiol-Bearing DOTA Complex of Gadolinium.
- Authors: Guntle GP, Jagadish B, Mash EA, Powis G, Dorr RT, Raghunand N
- Issue date: 2012 Jun
- Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity.
- Authors: Zhao H, Ning S, Scicinski J, Oronsky B, Knox SJ, Peehl DM
- Issue date: 2015 Dec 22
- Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001.
- Authors: Ning S, Sekar TV, Scicinski J, Oronsky B, Peehl DM, Knox SJ, Paulmurugan R
- Issue date: 2015 Aug 28
- RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors.
- Authors: Oronsky B, Scicinski J, Cabrales P, Minchinton A
- Issue date: 2016
- DCE-MRI using small-molecular and albumin-binding contrast agents in experimental carcinomas with different stromal content.
- Authors: Farace P, Merigo F, Fiorini S, Nicolato E, Tambalo S, Daducci A, Degrassi A, Sbarbati A, Rubello D, Marzola P
- Issue date: 2011 Apr